Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
58,837,653
-
Total 13F shares
-
2,653,572
-
Share change
-
-939,476
-
Total reported value
-
$45,217,425
-
Put/Call ratio
-
39%
-
Price per share
-
$17.04
-
Number of holders
-
8
-
Value change
-
-$9,749,337
-
Number of buys
-
3
-
Number of sells
-
22
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) as of Q1 2024
As of 31 Mar 2024 Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) had 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,653,572 shares of stock of the company.
Largest 10 holders included MORGAN STANLEY, CITADEL ADVISORS LLC, DEUTSCHE BANK AG\, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Bank of New York Mellon Corp, Birchview Capital, LP, Legal & General Group Plc, JPMORGAN CHASE & CO, NEW YORK STATE COMMON RETIREMENT FUND, and Royal Bank of Canada.
This table shows 11 institutional shareholders of the security as of 31 Mar 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.